Cerner this week introduced the creation of Cerner Enviza, a brand new working unit centered on creating new approaches to information administration for all times sciences analysis and improvement of recent therapies and therapies.
WHY IT MATTERS
The brand new unit is aimed toward serving to researchers drive insights from a number of information sources and real-world proof, Cerner says, in hopes of enabling quicker and extra environment friendly improvement of therapies and therapeutics.
The corporate notes that new therapies can usually take greater than 15 years and price $2.5 billion from discovery to deployment. Officers say Cerner Enviza is supposed to assist life sciences researchers “unlock the facility of information and a community of research-ready well being techniques to assist get therapies to sufferers extra shortly and at much less expense.”
One focus of the brand new unit can be to increase participation in scientific trials to assist obtain extra equitable outcomes, in line with Cerner – which factors out that as few as 3% of physicians and sufferers take part in trials​, with even fewer sufferers really receiving the brand new therapies which might be developed by way of these insights​.
By leveraging digital well being data, affected person registries and cohort research, oncology information and extra, Cerner Enviza was launched to assist healthcare and life sciences organizations with product commercialization, real-world proof and analytics, regulatory and issues of safety, and remedy specializations.    Â
THE LARGER TREND
This previous April, Cerner accomplished its acquisition of Kantar Well being – with its deep analytics experience in areas reminiscent of Alzheimer’s, most cancers analysis, uncommon illnesses and extra – for $375 million in money.
Collectively, the 2 corporations sought to “allow the acceleration of innovation and elevate our experience in addressing probably the most advanced scientific analysis questions altering the way in which healthcare is developed and delivered,” mentioned Kantar CEO Lynette Cooke on the time. (Cooke will now function government advisor to Cerner Enviza.)
Enviza is the primary new enterprise unit launched below Cerner’s new CEO, Dr. David Feinberg, who took the reins simply this month.
In a speech two weeks in the past, he highlighted a few of Cerner’s new applied sciences, and identified some areas the place he promised enhancements can be made.
“Information to do extra nice issues even quicker, that is the brass ring,” mentioned Feinberg. “The pipes are laid, which is great, however we’ve to make it simpler to get the appropriate info to the appropriate individuals on the proper time to eradicate that noise.”
ON THE RECORD
“With Cerner Enviza, we deliver collectively the experience, belongings and capabilities of Kantar Well being with Cerner’s expertise and entry to a big assortment of deidentified affected person well being information,” mentioned Mike Kelly, world head of Cerner Enviza, in an announcement. “Our method unites the life sciences and healthcare suppliers to assist analysis and trial alternatives throughout this ecosystem. The objective is to considerably cut back the timeframe and price from concept to remedy supply to assist obtain higher affected person outcomes.”
“We’ve got to interrupt down trade silos and evolve from merely accumulating information to producing significant insights that may speed up remedy improvement,” added Feinberg. “We will arm researchers with numerous instruments and datasets to assist them handle these challenges and assist change the way in which we develop and ship look after our sufferers.”
Twitter:Â @MikeMiliardHITN
E-mail the author:Â mike.miliard@himssmedia.com
Healthcare IT Information is a HIMSS publication.
